Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 6, 2014
Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantationFlorence Baychelier, Abla Achour, Stéphanie Nguyen, et al.International Journal of Cancer|August 14, 2012
Distinct tumor protein p53 mutants in breast cancer subgroupsAnne Dumay, Jean-Paul Feugeas, Evelyne Wittmer, et al.Cancer|March 19, 2013
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapyDavid Groheux, Mathieu Hatt, Elif Hindié, et al.Diabetes Care|August 17, 2013
Risk of breast cancer by individual insulin use: an international multicenter studyLamiae Grimaldi-Bensouda, David Cameron, Michel Marty, et al.The Oncologist|March 16, 2010
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancersJacqueline Lehmann-Che, Fabrice André, Christine Desmedt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2019
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 TrialAnne-Sophie Hamy, Sandrine Tury, Xiaofei Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupMichel Marty, Francesco Cognetti, Dominique Maraninchi, et al.Anticancer Research|March 2, 2018
COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer PatientsPatricia DE Cremoux, Anne-Sophie Hamy, Jacqueline Lehmann-Che, et al.BMC Cancer|June 3, 2011
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia de Cremoux, Fabien Valet, David Gentien, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusSylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.Pageof 6